Arcturus Therapeutics Holdings (ARCT) EBITDA (2018 - 2026)

Arcturus Therapeutics Holdings has reported EBITDA for 9 years, with the latest figure at -$27.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 91.56% year-over-year to -$27.0 million; the trailing twelve-month figure through Mar 2026 stood at -$78.7 million (down 15.35% YoY), and the FY2025 full-year result was -$65.8 million, up 18.73% from the prior year.
• EBITDA for Q1 2026 stood at -$27.0 million, up from -$29.1 million in the prior quarter.
• The five-year high for EBITDA was $117.3 million in Q4 2022, with the low at -$52.6 million in Q2 2023.
• Historically, EBITDA has averaged -$11.4 million across 5 years, with a median of -$17.2 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA soared 403.51% — and 2024, when it tumbled 156.3%.
• Arcturus Therapeutics Holdings' EBITDA stood at $117.3 million in 2022, then tumbled by 109.98% to -$11.7 million in 2023, then sank by 156.3% to -$30.0 million in 2024, then rose by 3.09% to -$29.1 million in 2025, then gained by 7.27% to -$27.0 million in 2026.
• The last three EBITDA figures came in at -$27.0 million (Q1 2026), -$29.1 million (Q4 2025), and -$13.4 million (Q3 2025), per Business Quant data.